̽»¨ºÏ¼¯

This guideline was developed to help clinicians determine when the risks of continued BZD prescribing outweigh the benefits for a given patient and how to safely taper the medication when indicated. Existing guidelines generally recommend limiting duration of BZD use to 2-4 weeks (except for limited conditions such as severe treatment-resistant generalized anxiety disorder, complex seizure disorders, spasticity, and sleep disorders involving abnormal movements). However, long-term BZD prescribing remains prevalent.

Guest Editorial: New Clinical Practice Guideline - Benzodiazepine Tapering

Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality

Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders

Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl

Beyond Buprenorphine in the ED: Leveraging Lessons From 10 Years of Implementation

The opioid toxicity crisis remains an urgent public health priority across the US and Canada. Since the seminal randomized controlled trial published in 2015 found that buprenorphine initiation in the emergency department (ED) was superior compared with referral to treatment alone, buprenorphine initiation in the ED has been hailed as an important mechanism for addressing the overdose crisis.

Current Advances in Behavioral Addictions

Review of Evidence on Alcohol and Health

2024 ASAM Weekly Guest Editorials